Dr. Arnold currently serves as CSO at Biocept. In 2010 he founded AEGEA Biotechnologies to acquire, develop, and commercialize, next generation nucleic acid technologies. Dr. Arnold also serves on the board of directors of Asuragen, as well as on the board of AEGEA. Previously, Dr. Arnold held various senior scientific and management positions at Molecular Biosystems (co-founder), Gen-Probe, Genta, Synteni, Incyte Genomics, and Oasis Biosciences (co-founder). Additionally, Dr. Arnold was a faculty member in the UCSD School of Medicine and a member of the UCSD Cancer Center. He is an inventor or co-inventor on 44 issued U.S. patents and more than 140 issued and pending patents worldwide. Dr. Arnold has authored more than 50 scientific publications. He received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.
Use of ctDNA and CTCs in the Biomarker Identification and Monitoring of Patients with Cancer
Tuesday, 17 November 2015 at 15:00
Add to Calendar ▼2015-11-17 15:00:002015-11-17 16:00:00Europe/LondonUse of ctDNA and CTCs in the Biomarker Identification and Monitoring of Patients with CancerSELECTBIOenquiries@selectbiosciences.com
Liquid biopsies offer the opportunity to interrogate a number of different target sample types, including ctDNA and CTCs. At Biocept both ctDNA and CTCs are used for identifying medically actionable biomarkers to assist in the optimal treatment of patients. A highly sensitive Target-SelectorTM assay is used for analysis of ctDNA which can detect better than 1:10,000 (mutant:wild-type). At the same time, a patented microchannel is used for isolating and interrogating CTCs at the single cell level. CTCs are enriched up to 50,000 fold and clinically actionable biomarkers are analyzed directly in the microchannel. The combination of these technologies has enabled the clinical validation of an array of biomarkers from single blood samples. These include mutational analysis for EGFR, KRAS, and BRAF, as well as FISH and protein analysis for HER2, FGFR1, MET, ALK, ROS1, ER, and PDL-1 across a range of cancer types.
Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonHigh-Value DiagnosticsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-11-17 15:00:002015-11-17 16:00:00Europe/LondonUse of ctDNA and CTCs in the Biomarker Identification and Monitoring of Patients with CancerSELECTBIOenquiries@selectbiosciences.com
